TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a hold rating in a report released on Thursday,Zacks reports.

Several other equities analysts have also recently commented on the stock. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. HC Wainwright began coverage on shares of TriSalus Life Sciences in a report on Wednesday. They issued a “buy” rating and a $11.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Finally, Lake Street Capital reduced their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Hold” and an average price target of $8.67.

TriSalus Life Sciences Price Performance

TLSI opened at $4.66 on Thursday. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a market capitalization of $286.96 million, a price-to-earnings ratio of -3.58 and a beta of 0.44. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05. The firm has a 50-day moving average price of $4.75 and a 200-day moving average price of $4.33.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million. Equities analysts expect that TriSalus Life Sciences will post -0.31 EPS for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the 1st quarter worth $20,267,000. BlackRock Inc. bought a new position in TriSalus Life Sciences in the second quarter valued at $12,099,000. Nantahala Capital Management LLC bought a new position in TriSalus Life Sciences in the second quarter valued at $10,900,000. Wasatch Advisors LP purchased a new stake in TriSalus Life Sciences during the first quarter valued at about $5,752,000. Finally, Vanguard Group Inc. raised its position in TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares in the last quarter. Institutional investors own 2.58% of the company’s stock.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and an $11.00 price target, implying approximately 135.5% upside from the referenced $4.67 share price. The recommendation provides new analyst visibility and supports the bullish case for TLSI. HC Wainwright initiates coverage of TriSalus Life Sciences with a Buy rating
• Positive Sentiment: HC Wainwright’s forecasts point to improving long-term profitability. The firm estimates EPS of $0.09 in fiscal 2028, $0.57 in 2029 and $1.02 in 2030, suggesting expectations for substantial earnings growth as TriSalus expands its business.
• Neutral Sentiment: The analyst still expects losses through fiscal 2027, including EPS of negative $0.31 for 2026 and negative $0.28 for 2027. Quarterly loss estimates improve from negative $0.12 in the third quarter of 2026 to negative $0.02 in the fourth quarter of 2027, indicating gradual progress but continued reliance on execution and financing before profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 10, unchanged from the prior period. This indicates no measurable short-squeeze setup, but also no significant disclosed bearish short positioning.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.